Loading...
•
Sep 30, 2021
Ampio Q3 2021 Earnings Report
Ampio Pharmaceuticals reported financial results for Q3 2021 and provided a business update.
Key Takeaways
Ampio Pharmaceuticals reported cash and cash equivalents of $17.1 million. They also reported a net loss of $3.628 million, or $0.02 per share.
Cash and cash equivalents totaled $17.1 million as of September 30, 2021.
The osteoarthritis Phase 3 pivotal trial database has been locked and data is being analyzed.
Enrollment and treatment of COVID-19 patients in India has commenced for the Phase 2 AP-019 study.
Ampio continues to investigate Ampion’s potential in new indications within the preclinical space.
Ampio
Ampio
Forward Guidance
Ampio expects to have cash and cash equivalents along with access to external sources of liquidity sufficient to fund its business operations through the first quarter of 2023.